Clinical trials: Primary Open - Angle Glaucoma (POAG)
Glaucoma Open-Angle Primary, Ocular Hypertension
Open-Label Study of Safety of H1337 in Healthy Volunteers
The trial will evaluate the safety of one dose regimen of H-1337 [1% twice daily (b.i.d.)] in both eyes in healthy volunteers.
- Trial name
- NCT06572397
- Testing
- H-1337 1.0%
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- D. Western Therapeutics Institute, Inc.
Glaucoma
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01514734
- Testing
- Brinzolamide/timolol maleate fixed combination
- Where
- Brazil
- Volunteers
- 9 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma
Effect of Xen Implantation on the Aqueous Humor Proteome
The purpose of this study is to determine how the aqueous humor proteome changes after implantation of a Xen microstent for treatment of glaucoma.
- Trial name
- NCT04141865
- Testing
- Xen, Aqueous shunt
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Price Vision Group
Primary Open Angle Glaucoma (POAG)
Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG)
The purpose of this study is to evaluate the safety and performance of the ARGOS-IO system in patients with POAG and indicated cataract surgery.
- Trial name
- NCT02434692
- Testing
- ARGOS-IO system
- Where
- 11 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
This study is evaluating a new eye drop containing pregabalin (TB0001) as a potential treatment for people with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT07913074
- Testing
- Arm 1: TB0001 ophthalmic solution 0.9%, Arm 2: TB0001 ophthalmic solution 1.2%, TB0001 ophthalmic solution 1.5%
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Tavo Biotherapeutics
Glaucoma and Ocular Hypertension
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
The purpose of this study is to investigate the safety and efficacy of up to three concentrations of DE-117 ophthalmic solution (Low Dose, Medium Dose, and High Dose) as monotherapy and as adjunctive therapy (DE-117 ophthalmic…
- Trial name
- NCT01654484
- Testing
- DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Santen Inc.
Glaucoma
Evaluate the Efficacy and Safety of Glaucoma Implant in Primary Open Angle Glaucoma
The objective of this study is to evaluate the efficacy and safety of glaucoma device in the treatment of primary open-angle glaucoma.
- Trial name
- NCT05892185
- Testing
- GELA, XEN
- Volunteers
- 20 people
- Sponsor
- Mingche Biotechnology CO., LTD
Glaucoma
POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma
This is an open-label, randomized, multi-center, active-controlled parallel-comparison of POLAT-001 to latanoprost ophthalmic solution in patients with ocular hypertension and primary open-angle glaucoma.
- Trial name
- NCT02466399
- Testing
- POLAT-001, Latanoprost ophthalmic solution
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Peregrine Ophthalmic
Ocular Hypertension, Primary Open-angle Glaucoma
BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension
The purpose of this study is to evaluate the clinical efficacy of the BREMEN eye drops in the treatment of primary open-angle glaucoma or intraocular hypertension.
- Trial name
- NCT03235232
- Testing
- BREMEN eye drops, Combigan®
- Where
- Brazil
- Volunteers
- 406 people
- Sponsor
- EMS
Primary Open Angle Glaucoma, Ocular Hypertension
A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.
To investigate dose response, safety and efficacy of PF-03187207 in patients with primary open-angle glaucoma or ocular hypertension
- Trial name
- NCT00595101
- Testing
- PF-03187207, Latanoprost 0.005%, PF-03187207 Vehicle
- Where
- 13 sites in Japan
- Volunteers
- 117 people
- Sponsor
- Bausch & Lomb Incorporated
Primary Open Angle Glaucoma, Ocular Hypertension
A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
To investigate whether the IOP lowering efficacy of STN1012600 ophthalmic solution 0.002% is non-inferior to that of latanoprost 0.005% in subjects with POAG or OHT after treatment for 4 weeks.
- Trial name
- NCT05495061
- Testing
- STN1012600 ophthalmic solution 0.002%, Latanoprost ophthalmic solution 0.005%
- Where
- 44 sites in Japan
- Volunteers
- 325 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open-angle Glaucoma, Ocular Hypertension
A Clinical Study to Evaluate the Efficacy and Safety of CKD-351
The purpose of this study is to evaluate efficacy and safety of CKD-351.
- Trial name
- NCT03762369
- Testing
- CKD-351, Latanoprost, D930
- Where
- South Korea
- Volunteers
- 384 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Glaucoma
Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol
The purpose of this study was to assess the safety and intraocular pressure (IOP)-lowering efficacy of changing to DuoTrav® from prior timolol 0.5% monotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01336569
- Testing
- Travoprost 0.004%/timolol maleate 0.5% fixed combination
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Glaucoma
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
The purpose of the study is to assess the safety, tolerability, and IOP effects of RO5093151 following 7 days of topical ocular treatment in patients with primary open angle glaucoma or ocular hypertension.
- Trial name
- NCT02622334
- Testing
- Latanoprost, RO5093151
- Where
- 7 sites in United States, Singapore
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche